Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer

Roy XiaoCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA;Medical Research Scholars Program, National Institutes of Health, Bethesda, MD, USA;Tumor Biology Section, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA

http://orcid.org/0000-0003-4459-0746 View further author information

Clint T. AllenNational Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA;Department of Otolaryngology – Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USAView further author information

Linda TranNational Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA

http://orcid.org/0000-0001-7080-5320 View further author information

Priya PatelMedical Research Scholars Program, National Institutes of Health, Bethesda, MD, USA;Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USAView further author information

So-Jin ParkNational Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USAView further author information

Zhong ChenTumor Biology Section, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USAView further author information

Carter Van WaesTumor Biology Section, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USAView further author information

Nicole C. SchmittNational Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA;Department of Otolaryngology – Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USACorrespondence[email protected]
View further author information

show all

Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date